First Quadrant’s Vanda Pharmaceuticals VNDA Stock Holding History

First Quadrant’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-55,400	Closed	-$869K	–	515
2021 Q4	$869K	Hold	55,400	–	–	0.09%	181
2021 Q3	$950K	Hold	55,400	–	–	0.11%	161
2021 Q2	$1.19M	Hold	55,400	–	–	0.14%	143
2021 Q1	$832K	Buy	+55,400	New	+$897K	0.09%	186
2020 Q3	–	Sell	-4,365	Closed	-$50K	–	720
2020 Q2	$50K	Sell	4,365 -42,095	-91%	-$477K	0.01%	632
2020 Q1	$481K	Buy	+46,460	New	+$576K	0.07%	271
2019 Q2	–	Sell	-32,011	Closed	-$589K	–	756
2019 Q1	$589K	Buy	32,011 +2,211	+7%	+$50.4K	0.05%	336
2018 Q4	$779K	Sell	29,800 -7,229	-20%	-$170K	0.06%	272
2018 Q3	$850K	Sell	37,029 -7,111	-16%	-$145K	0.02%	407
2018 Q2	$841K	Hold	44,140	–	–	0.02%	424
2018 Q1	$744K	Buy	+44,140	New	+$739K	0.01%	433
2015 Q4	–	Sell	-400	Closed	-$5K	–	843
2015 Q3	$5K	Buy	+400	New	+$4.89K	﹤0.01%	783

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

First Quadrant's VNDA Position: Q1 2022 in Review

First Quadrant sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 55,400 shares — an estimated $869K sold.

First Quadrant first reported a position in VNDA in Q3 2015 and held it in 12 quarters. The position peaked at $1.19M in Q2 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

First Quadrant reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 55,400 Vanda Pharmaceuticals shares in Q1 2022, an estimated $869K.
First Quadrant first reported a position in Vanda Pharmaceuticals in Q3 2015 and held it in 12 quarters.
First Quadrant's Vanda Pharmaceuticals position peaked at $1.19M in Q2 2021.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.